All News

podcast logo

RheumNow Podcast – Rheum Lives Matter (8.28.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week. Of mice and men in cartilage, the efficacy of JAK inhibitors in patients who are having skin problems, nrAxSpa has its own diagnostic code, metformin, talking about Back Talk, plus so much more.

Read Article
sperm.fertilization.preg_.jpg

Filgotinib Decision Delayed by FDA

Jack Cush, MD

On August 18th, Gilead and Galapagos received a complete response letter from the FDA, which will delay consideration of filgotinib for the treatment of moderate-to-severe RA.

Read Article
podcast logo

RheumNow Podcast - The SARS-CoV-2 Update (8-14-20)

Jack Cush, MD

Dr. Jack Cush updates the news and journal articles from the past week on RheumNow.com, with information on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors.

Read Article
COVID infection mask

Rheumatic Diseases, Drugs and COVID-19 Guidelines

Jack Cush, MD

Several recent publications have focused on the risk and outcomes of rheumatic disease (RDD) and autoimmune patients who become infected with SARs-CoV-2.

Read Article
LBP.red_.jpg

Secukinumab Effective in Non-Radiographic Axial SpA

Jack Cush, MD

The PREVENT trial was a one year, phase III study that showed significant benefits when secukinumab (SEC) was given to patients with active non‐radiographic axial spondyloarthritis (nr‐axSpA) for 52 weeks.

Read Article
podcast logo

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jack Cush, MD

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article
podcast logo

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jack Cush, MD

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article
Non-Radiographic Axial Spondyloarthritis has Its Own Diagnostic Code; As of October 2020, nr-axSpA will be officially included in the 10th version of the International Classification of Diseases (ICD-10) coding manual as M46.8 https://t.co/AftIecd2z3 https://t.co/973yJUW57p

Links:

Dr. John Cush RheumNow ( View Tweet)
AbbVie has submited Regulatory Application to FDA and EMA for upadacitinib proposed indication to treate active Ankylosing Spondylitis https://t.co/RPaOXCarEZ

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast - The SARS-CoV-2 Update (8-14-20) Dr. Jack Cush highlights the latest numbers on COVID-19 and its impact on Rheumatic Patients. Also, Top 4 best sellers, new take on NR-Ax-SpA & enthesitis https://t.co/IJAHGynSNd

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up: The SARS-CoV-2 Update with info on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors. Watch it here> https://t.co/1WUZQJajgW or podcast listen here>> https://t.co/IJAHGynSNd

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic literature finds a connection between ankylosing spondylitis (AS) and dementia (RR 1.19 [95% CI 1.01‐1.41]). From a total of 6562 articles reviewed, only 4 met criteria - analysis included 156418 pts. Cause? inflammation, inactivity?

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 10 studies ( p534 patients) shows that exercise in ankylosing spondylitis improves pain, function and disease activity. Statistically signif improvement in pain (P<0.0001), BASDAI (P <0.00001), and BASFI (P<0.00001), but not CRP and ESR. https://t.co/fKo9kNOrmO

Links:

Dr. John Cush RheumNow ( View Tweet)

CORRONA: 477 axSpA pts showed 25% having enthesitis (3.9 sites) at enrollment. Enthesitis pts were more likely to be female w/ nonradiographic axSpA, more likely to be Rx w/ biologic or DMARD; & Overall - had more disease activity (TJC, SJC, ASAS,BASDAI) https://t.co/weQC798mck

Links:

Dr. John Cush RheumNow ( View Tweet)

Single center retrospective Korean study of 1280 Ankylosing Spondylitis patients (595 exposed to TNFi) showed that TNFi was associated with significantly decreased Xray change rate (mSASSS) (β=−0.112, p=0.004). https://t.co/W4j0Ckt0R2

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has approved a 6th adalimumab biosimilar - called Hulio (adalimumab-fkjp) with indications of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, psoriasis. https://t.co/zMNsDjVewU

Links:

Dr. John Cush RheumNow ( View Tweet)

African-Americans with Ank Spondylitis have worse disease compared to whites. Study of 10,990 AS patients shows AA to have high frequency of anterior uveitis, hypertension, diabetes, depression, and heart disease and higher ESR and CRP levels. https://t.co/YyLqlM85sD

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT @52wk. Significant improvement in ASAS40, BASDAI50&amp; ASdAS-CRP ID. MRI BME score significantly decreased (-1.68&amp;-1.03 (no LD) vs -0.39 PBO) @RheumNow https://t.co/5sDAZRhmzW https://t.co/cDjduG38lr

Links:

Dr. John Cush RheumNow ( View Tweet)
UK population study shows fibromyalgia pts have a higher risk of Self harm (HR 2.06; 1.60,2.65)), RA (HR 1.59) & OA, but not ank spondylitis. Pain and depression are risk factors for self-harm & self harm is a key risk factor for suicide.https://t.co/vXmZKYq3Pe

Links:

Dr. John Cush RheumNow ( View Tweet)

CHMP of the EMA has recommended approval of intravenous & subcutaneous formulations of CT-P13 (Remsima) for use in 5 conditions - Crohn, UC, ankylosing spondylitis, PsA & psoriasis. Remsima dose is 120 mg q 2wks regardless of body weight. https://t.co/eDUCvQost9

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×